[1] Zhu JZ, Zhou QY, Wang YM, et al. Prevalence of fatty liver disease and the economy in China: A systematic review. World J Gastroenterol, 2015, 21: 5695-5706.
[2] Younossi ZM, Koenig AB, Abdelatif D, et al. Global epide-miology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology, 2016, 64: 73-84.
[3] Wei JL, Leung JC, Loong TC, et al. Prevalence and severity of nonalcoholic fatty liver disease in non-obese patients: a population study using proton-magnetic resonance spectroscopy. Am J Gastroenterol, 2015, 110: 1306-1314.
[4] Feng RN, Du SS, Wang C, et al. Lean-non-alcoholic fatty liver disease increases risk for metabolic disorders in a normal weight Chinese population. World J Gastroenterol, 2014, 20: 17932-17940.
[5] Lin YC, Chang PF, Hu FC, et al. A common variant in the PNPLA3 gene is a risk factor for non-alcoholic fatty liver disease in obese Taiwanese children. J Pediatr, 2011, 158: 740-744.
[6] Goffredo M, Caprio S, Feldstein AE, et al. Role of TM6SF2 rs58542926 in the pathogenesis of nonalcoholic pediatric fatty liver disease: A multiethnic study. Hepatology, 2016, 63: 117-125.
[7] Mili? S, Luli? D, ?timac D. Non-alcoholic fatty liver disease and obesity: biochemical, metabolic and clinical presentations. World J Gastroenterol, 2014, 20: 9330-9337.
[8] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018更新版). 临床肝胆病杂志,2018, 34: 947-957.
[9] Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guid-ance from the American Association for the Study of Liver Diseases. Hepatology, 2018, 67: 328-357.
[10] WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet, 2004, 363: 157-163.
[11] Liu CJ. Prevalence and risk factors for non-alcoholic fatty liver disease in Asian people who are not obese. J Gastroenterol Hepatol, 2012, 27: 1555-1560.
[12] Eguchi Y, Hyogo H, Ono M, et al. Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study. J Gastroenterol, 2012, 47: 586-595.
[13] Kim D, WR Kim. Nonobese fatty liver disease. Clinical Gastroenterology and Hepatology, 2017, 15: 474-485.
[14] Chang Y, Ryu S, Sung E, et al. Weight gain within the normal weight range predicts ultrasonographically detected fatty liver in healthy Korean men. Gut, 2009, 58: 1419-1425.
[15] Das K, Das K, Mukherjee PS, et al. Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease. Hepatology, 2010, 51: 1593-1602.
[16] Bouchi R, Takeuchi T, Akihisa M, et al. Increased visceral adiposity with normal weight is associated with the prevalence of non-alcoholic fatty liver disease in Japanese patients with type 2 diabetes. J Diabetes Investig, 2016, 7: 607-614.
[17] Adams LA, Marsh JA, Ayonrinde OT, et al. Cholesteryl ester transfer protein gene polymorphisms increase the risk of fatty liver in females independent of adiposity. J Gastroenterol Hepatol, 2012, 27: 1520-1527.
[18] Musso G, Cassader M, Bo S, et al. Sterol regulatory element-binding factor 2 (SREBF-2) predicts 7-year NAFLD incidence and severity of liver disease and lipoprotein and glucose dysmeta-bolism. Diabetes, 2013, 62: 1109-1120.
[19] Yasutake K, Nakamuta M, Shima Y, et al. Nutritional inves-tigation of non-obese patients with non-alcoholic fatty liver disease: the significance of dietary cholesterol. Scand J Gastroenterol, 2009, 44: 471-477.
[20] Younossi ZM, Stepanova M, Negro F, et al. Nonalcoholic fatty liver disease in lean individuals in the United States. Medicine (Baltimore), 2012, 91: 319-327.
[21] Sookoian S, Pirola CJ. Systematic review with meta-analysis: risk factors for non-alcoholic fatty liver disease suggest a shared altered metabolic and cardiovascular profile between lean and obese patients. Aliment Pharmacol Ther, 2017, 46: 85-95.
[22] Sookoian S, Pirola CJ. Systematic review with meta-analysis: the significance of histological disease severity in lean patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther, 2018, 47: 16-25.
[23] Kim NH, Kim JH, Kim YJ, et al. Clinical and metabolic factors associated with development and regression of nona-lcoholic fatty liver disease in nonobese subjects. Liver Int, 2014, 34: 604-611.
[24] Shen J, Wong GL, Chan HL, et al. PNPLA3 gene poly-morphism and response to lifestyle modification in patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol, 2015, 30: 139-146.
[25] Yu D, Shu XO, Xiang YB, et al. Higher dietary choline intake is associated with lower risk of nonalcoholic fatty liver in normal-weight Chinese women. J Nutr, 2014, 144: 2034-2040.
[26] Mofidi F, Poustchi H, Yari Z, et al. Synbiotic supplementation in lean patients with non-alcoholic fatty liver disease: a pilot, randomized, double-blind, placebo-controlled, clinical trial. Br J Nutr, 2017, 117: 662-668. |
